# F4 scope fidelity result

```yaml
evidence_id: PERSONALIZED_PRESCRIPTION_ALGORITHM_V2_FINAL_4
verified_at_kst: 2026-08-24
status: APPROVE_SCOPE_FIDELITY_ONLY
review_mode: INDEPENDENT_READ_ONLY
commit_created: false
push_performed: false
deployment_claimed: false
```

The final independent read-only F4 review returned `APPROVE` for scope fidelity. It found no new authorization or implementation path for:

- 100m, 200m, 400m, sprint, or ATP-PC detailed prescription;
- unsourced numeric taper, load metric, or arbitrary dose increase;
- raw memo, note, symptom clause, evidence clause, or free-text adaptation;
- journal, completion, attendance, points, badges, streaks, or reward-driven automatic increase;
- backend, account, payment, or remote-coach expansion;
- in-place rewriting of legacy v1/v2 bytes;
- deployment, canonical promotion, or OPEN issue closure.

The active adaptation registry still contains only two same-pair `VOLUME` support-duration edges. `FREQUENCY` and `INTENSITY` remain inactive, numeric taper authority remains `NOT_GRANTED`, race-date retention remains `NOT_AUTHORIZED`, and compiled race-placement rows remain zero.

The reviewer directly passed the authority, taper, and race-placement validators and an impl regression subset. Its app Vitest attempt was blocked by its read-only sandbox, so the executor's raw final app JSON and browser logs remain the evidence for app-wide execution; that limitation is not relabeled as an independent app test pass.

This F4 approval is not an F1 approval, release approval, or deployment receipt.

[DRAFT_COMPLETE]
